Frutarom Granted Product License for Benolea® by Canada NHPD

The Canadian Natural Health Products Directorate (NHPD) granted Frutarom, a product license for its Benolea® cardiovascular health support ingredient. Benolea supports cardiovascular health by maintaining healthy blood pressure levels[1]. A recent clinical study by Endang Susalit, PhD, et al, showed that extract of olive leaf (Olea europaea) was effective in patients with stage-1 hypertension, demonstrating that Benolea can lower blood pressure[2]. As of December, Benolea, manufactured in Wadinswil, Switzerland, using Frutarom’s proprietary HyperPure process, will be available to local dietary supplement manufacturers in Canada.

Benolea will be marketed in Canada by CK Ingredients, an Ontario, Canada-based distributor of specialty food and supplement ingredients.

According to The Heart and Stroke Foundation, research affirms that heart/cardiovascular disease is the No.1 killer in Canada. It also is the most costly disease in Canada, placing the greatest burden on the national health care system. Based on the latest available heart disease and stroke statistics, about 40% of Canadians have high blood cholesterol (Statistics Canada, 2012), and nearly 20% of Canadian adults (about 6 million) have high blood pressure (Wilkins et al, 2010).

Since ancient times, olive leaves have been used for medicinal purposes, exhibiting a wide range of activity, especially for cardiovascular health. Benolea offers the health benefit of olive leaves in a very convenient form for dietary supplement manufacturers

“We are excited to receive the Products Licence for Benolea® from The Canadian Natural Health Products Directorate (NHPD),” says Yannick Capelle, Product Manager for Frutarom Health. “Benolea is already marketed successfully as dietary supplements successful sold in the US, Germany, Finland and Bulgaria. We are confident Canada may now also benefit from the introduction of similar products.

[1] Subject to certain limitations set out in said license

[2] Susalit E, et al. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension

Algatechnologies Invests $20 million in Natural Astaxanthin Production

Algatechnologies (“Algatech”), Israel, announces a more than 100% expansion of its production capacity of AstaPure® brand natural astaxanthin. This doubling of capacity follows an investment of $20 million in its state-of-the-art facility in the Arava Desert, Israel.

This significant step is only part of the transformation by Algatech’ new owners, Grovepoint, since the UK investment group acquired control of Algatech in 2013. Grovepoint’s distinct aim is development and capitalization of the potential business in natural astaxanthin and related products.

“The expansion will be executed in phases, with a substantial part to be completed in 2014,” says Hagai Stadler, CEO of Algatech. “Part of the new plant is dedicated specifically for production of new microalgae products, based on our expertise and capabilities in the microalgae cultivation process. Innovative technologies will be merged into the current process to increase the facility yield and to reduce costs”

The past few years have witnessed dramatic growth in awareness of the health benefits of natural astaxanthin. This stems from the publication of a number of important clinical trials showing that regular consumption of astaxanthin helps protect the body from health disorders related to oxidative stress.

“This expansion of the production of astaxanthin from microalgae will allow Algatech to maintain its significant leadership position in existing markets as well as leverage it to develop new ones,” adds Leon Blitz, Grovepoint leading director.

The AstaPure® brand is sold mainly in North America, Europe and Asia as an active ingredient in dietary supplements, cosmetics and functional foods and beverages.

“The expansion is symbol of trust on the future of the natural astaxanthin, and in it growth in the coming years” says Ed Hofland, Algatech Chairman.

Related articles